Joseph Group Capital Management Boosts Position in Medpace Holdings, Inc. (NASDAQ:MEDP)

Joseph Group Capital Management boosted its position in Medpace Holdings, Inc. (NASDAQ:MEDP) by 18.9% during the 4th quarter, HoldingsChannel reports. The firm owned 3,620 shares of the company’s stock after purchasing an additional 575 shares during the period. Joseph Group Capital Management’s holdings in Medpace were worth $1,203,000 as of its most recent filing with the SEC.

A number of other large investors have also made changes to their positions in the company. R Squared Ltd bought a new stake in Medpace during the fourth quarter valued at approximately $30,000. SBI Securities Co. Ltd. bought a new stake in shares of Medpace during the 4th quarter valued at $31,000. Jones Financial Companies Lllp increased its stake in shares of Medpace by 2,750.0% in the 4th quarter. Jones Financial Companies Lllp now owns 114 shares of the company’s stock worth $38,000 after purchasing an additional 110 shares in the last quarter. Lindbrook Capital LLC raised its holdings in Medpace by 27.6% in the 4th quarter. Lindbrook Capital LLC now owns 134 shares of the company’s stock worth $45,000 after purchasing an additional 29 shares during the period. Finally, True Wealth Design LLC lifted its position in Medpace by 16,800.0% during the third quarter. True Wealth Design LLC now owns 169 shares of the company’s stock valued at $56,000 after purchasing an additional 168 shares in the last quarter. 77.98% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of analysts have commented on the company. Leerink Partners began coverage on Medpace in a research report on Monday, March 24th. They issued a “market perform” rating and a $330.00 price target for the company. Robert W. Baird raised their target price on shares of Medpace from $354.00 to $362.00 and gave the stock a “neutral” rating in a research note on Monday, January 27th. Finally, Leerink Partnrs upgraded shares of Medpace to a “hold” rating in a research report on Monday, March 24th. Nine equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $376.30.

Medpace Stock Performance

Shares of NASDAQ:MEDP opened at $312.36 on Friday. The firm has a market cap of $9.52 billion, a price-to-earnings ratio of 24.73, a P/E/G ratio of 3.81 and a beta of 1.47. The firm has a fifty day moving average price of $335.90 and a 200 day moving average price of $339.15. Medpace Holdings, Inc. has a fifty-two week low of $302.01 and a fifty-two week high of $459.77.

Medpace (NASDAQ:MEDP) last issued its quarterly earnings data on Monday, February 10th. The company reported $3.67 earnings per share for the quarter, beating analysts’ consensus estimates of $2.96 by $0.71. Medpace had a return on equity of 51.48% and a net margin of 19.17%. As a group, research analysts predict that Medpace Holdings, Inc. will post 12.29 earnings per share for the current year.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.